ANGIOTENSIN CONVERTING ENZYMES (ACE) INHIBITORS MARKET ANALYSIS

Regional Analysis

Global Angiotensin Converting Enzymes (ACE) Inhibitors Market- Regional Insights

• North America is the largest market for angiotensin converting enzymes (ACE) inhibitors, accounting for around 42.5% of the global market in 2022. This is due to the high prevalence of cardiovascular diseases, well-established healthcare infrastructure, and a growing aging population. The region is characterized by a strong presence of pharmaceutical companies, which has facilitated research and development of ACE inhibitors. Additionally, robust healthcare reimbursement systems and increased awareness of cardiovascular health contribute to the sustained market expansion in North America. Moreover, increasing organic strategies such as product approval are expected to drive market growth over the forecast period. For instance, on February 17, 2023, Travere Therapeutics, a biopharmaceutical company headquartered in California, U.S., announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to FILSPARI (sparsentan), to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression, generally with a urine protein-to-creatinine ratio (UPCR) ≥1.5 g/g.
• Europe is the second largest market for angiotensin converting enzymes (ACE) inhibitors, accounting for around 28.7% of the global market in 2022. In Europe, the global angiotensin converting enzymes (ACE) inhibitors market presents a mature landscape, with a significant emphasis on healthcare access and quality. The European market has benefited from strong healthcare systems and comprehensive insurance coverage, which ensures easy access to medications. However, the market faces challenges due to stringent regulatory requirements and price controls in several European countries, which can impact profit margins for pharmaceutical companies. Despite these challenges, the global angiotensin converting enzymes (ACE) inhibitors market in Europe continues to grow steadily, driven by a rising geriatric population and the increasing burden of cardiovascular diseases. For instance, in 2019, the European Society of Cardiology published a report on a contemporary analysis of cardiovascular disease (CVD) statistics, which states that there are more than 6 million new cases of cardiovascular diseases in Europe and more than 11 million in Europe as a whole every year. With almost 49 million people living with the disease in Europe (EU), the cost to the EU economies is high at US 230.3 (€210) million a year.
• Asia Pacific is the fastest growing market for angiotensin converting enzymes (ACE) inhibitors, accounting for around 20.0% of the global market in 2022. In the Asia Pacific region, the angiotensin converting enzymes (ACE) inhibitors market is marked by dynamic growth opportunities. This is attributed to factors such as the expanding middle-class population, urbanization, and a rising awareness of the importance of cardiovascular health. Additionally, governments in several Asia Pacific countries are taking initiatives to improve healthcare infrastructure and access to medications, further fueling market growth. The pharmaceutical industry in the region is actively pursuing research and development efforts in the field of cardiovascular medicines, contributing to innovation in ACE inhibitors. The Asia Pacific market for ACE inhibitors is poised for significant expansion in the coming years, making it a promising area for market players to invest and establish a strong presence. Moreover, increasing awareness for heart diseases is expected to augment the market growth over the forecast period. For instance, on June 26, 2023, patient organizations, allied health professionals, academia, corporate partners launched the Asia Pacific Cardiovascular Disease Alliance (APAC CVD Alliance), a multisectoral coalition committed to improving heart health and reducing the CVD burden across nine countries in Asia (Australia, China, India, Indonesia, Japan, Malaysia, South Korea, Thailand, Vietnam) to tackle heart disease in Asia with our strategic partners – the Asia Pacific Federation for Clinical Biochemistry and Laboratory Medicine (APFCB), Global Alliance for Patient Access (GAfPA), Global Heart Hub (GHH), and Universiti Teknologi MARA (UiTM) Faculty of Medicine in Malaysia – and corporate partners Amgen, Novartis, and Roche Diagnostics, the APAC CVD Alliance.